2014
Topiramate Treatment for Heavy Drinkers: Moderation by a GRIK1 Polymorphism
Kranzler HR, Covault J, Feinn R, Armeli S, Tennen H, Arias AJ, Gelernter J, Pond T, Oncken C, Kampman KM. Topiramate Treatment for Heavy Drinkers: Moderation by a GRIK1 Polymorphism. American Journal Of Psychiatry 2014, 171: 445-452. PMID: 24525690, PMCID: PMC3997125, DOI: 10.1176/appi.ajp.2013.13081014.Peer-Reviewed Original ResearchConceptsHeavy drinking daysHeavy drinkersTopiramate treatmentDaily doseHeavy drinkingTopiramate's effectsDrinking daysAbstinent daysUse of topiramateMaximal daily doseWeeks of treatmentC allele homozygotesPersonalized treatment optionsEnzyme γ-glutamyl transpeptidasePlacebo groupΓ-glutamyl transpeptidaseTreatment optionsTreatment completionPharmacogenetic findingsTreatment goalsAlcohol-related problemsKainate receptorsTreatment groupsBrief counselingAlcohol dependence
2003
A Functional Polymorphism of the μ-Opioid Receptor Gene is Associated with Naltrexone Response in Alcohol-Dependent Patients
Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, O'Brien CP. A Functional Polymorphism of the μ-Opioid Receptor Gene is Associated with Naltrexone Response in Alcohol-Dependent Patients. Neuropsychopharmacology 2003, 28: 1546-1552. PMID: 12813472, DOI: 10.1038/sj.npp.1300219.Peer-Reviewed Original ResearchConceptsΜ-opioid receptorAlcohol-dependent patientsAbstinence ratesPlacebo-controlled clinical trialOverall abstinence ratesΜ-receptor antagonistWeeks of treatmentΜ-opioid receptor geneAlcohol-dependent individualsAsn40 alleleAsp40 alleleProperties of alcoholRelapse rateNaltrexone responseOpioid systemClinical trialsTreatment outcomesNaltrexoneFunctional polymorphismsGenotype groupsPatientsHeavy drinkingDrinking outcomesReceptor geneSpecific polymorphisms